Abstract 466P
Background
Extracellular matrix (ECM) plays a key role in tumorigenesis and progression. Collagen XII, expressed by the COL12A1 gene, is an important component of the ECM. COL12A1 is associated with tumorigenesis and poor prognosis in several cancers, but its role in breast cancer (BC) is unclear, especially the different expression between primary and metastasic foci of BC has not been reported.
Methods
We analyzed the expression of COL12A1 in tumor tissue and normal tissue, plotted a Kaplan-Meier curve by GEPIA, and analyzed mutation by COSMIC and cBioPortal in BC. PPI, GGI and pathway and process enrichment analysis were performed by STRING and Metascape. GeneMANIA was used to map gene interaction networks. BC cases with paired primary and metastatic foci were found out from TCGA database for analyzing different expression of COL12A1 in primary and metastatic foci. Immunohistochemical (IHC) staining was performed in paraffin tissue samples of paired primary lesion and lung metastases from triple-negative breast cancer (TNBC) patients.
Results
The results showed that COL12A1 in BC tissues was upregulated and was associated with poor prognosis of BC and the Luminal A+Luminal B subgroup. 3.04% of BC patients had COL12A1 gene alteration. Missense substitution (37.59%) was the most frequent mutation type. Among the 10 related genes, COL3A1, COL5A2, MMP12, P4HA1, P4HA2, P4HA3 and SERPINH1 were significantly upregulated in tumor tissue. The 20 most relevant genes in the GGI network are COL11A1, ID1, COL8A1, MMP9, COL5A1, MMP2, ISLR, LUM, COL7A1, COL3A1, COL1A2, MMP3, COL10A1, COL6A1, COL11A2, COL8A2, MMP8, MMP12. SERPINH1 and MMP13, which are enriched in several pathways including collagen degradation, collagen formation, collagen metabolic process, endodermal cell differentiation, collagen fibril organization and so on. Furthermore, analysis of paired cases from the TCGA-BRCA database revealed that COL12A1 was expressed with higher level in primary foci than metastatic foci. IHC staining revealed that the expression of COL12A1 was upregulated in primary foci of TNBC.
Conclusions
In conclusion, COL12A1 may be a poor prognostic predictor and a specific therapeutic target for primary foci in BC, especially in TNBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Suzhou Science and Technology Developing Projects (SKYD2022083, SYSD2020079 and SYSD2020075).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1266P - Prediction of lung cancer risk in ground-glass nodules using deep learning from CT images
Presenter: Anil Vachani
Session: Poster session 04
1267P - Enhancing pulmonary nodule diagnosis: A combinatorial model of cfDNA methylation, plasma proteins and LDCT imaging
Presenter: Meng Yang
Session: Poster session 04
1268P - Liquid biopsy and CT-based multi-omics fusion enhances differential diagnosis of early-stage lung adenocarcinoma
Presenter: Yanwei Zhang
Session: Poster session 04
1269P - Machine learning model for predicting lung cancer recurrence after surgical treatment: A retrospective study using NLST and European hospital data
Presenter: Ann Valter
Session: Poster session 04
1272P - Postoperative survival prediction in non-small cell lung cancer patients based on driver genotypes
Presenter: Huiting Wang
Session: Poster session 04
1273P - The prognostic value evaluation of a tissue Comprehensive Genomic Profiling (CGP)-informed personalized MRD detection assay in NSCLC
Presenter: Wei Gao
Session: Poster session 04
1274P - Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer
Presenter: Kyungmi Yang
Session: Poster session 04
1275P - Genomic analysis of lung adenocarcinoma with micropapillary component: Identification of micropapillary-related subtypes and development of a prognostic model
Presenter: Yuechun Lin
Session: Poster session 04
1276P - Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Kiyotaka Yoh
Session: Poster session 04